Ono Pharmaceutical Co., Ltd. OPHLF
14.90 USD -0.02 (-0.13%)
Nov 4, 2026, 11:08 AM EST
14.90 Day range 14.90
11.08 52-week range 18.67
- YTD
- +15.77%
- 1 year
- +22.13%
- Market cap
- 7.00B
- EPS (ttm)
- 1.01
- P/E ratio
- 14.75
- YTD return
- +15.77%
- 1-year return
- +22.13%
- Volume
- 1.00K
- Avg volume
- 542
- Open
- 14.90
- Previous close
- 14.92
- Day's range
- 14.90 – 14.90
- 52-week range
- 11.08 – 18.67
- Earnings date
- Oct 29, 2026
2Y +3.26 (+28.01%)
Next earnings
Oct 29, 2026
Expected Oct 29, 2026. Consensus EPS estimate 0.26.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Oct 29, 2026 | Sep 30, 2026 | 0.26 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 0.25 | 0.3193 | +0.07 | +27.72% |
| May 7, 2026 | Mar 31, 2026 | 0.05209 | 0.01 | -0.04 | -80.80% |
| Feb 1, 2026 | Dec 31, 2025 | 0.2888 | 0.40 | +0.11 | +38.50% |
| Oct 30, 2025 | Sep 30, 2025 | 0.2748 | 0.32 | +0.05 | +16.45% |
| Aug 4, 2025 | Jun 30, 2025 | 0.3432 | 0.26 | -0.08 | -24.24% |
News
Ono Pharma Announces Results From Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid Modulator 
Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Time to Sell? 
Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock? 
Reviewing Iterum Therapeutics (NASDAQ:ITRM) and Ono Pharmaceutical (OTCMKTS:OPHLF) 
Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases 
Are Investors Undervaluing Ono Pharmaceutical Co. (OPHLF) Right Now? 
Ono Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimates 
Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline 
Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength? 
Should Value Investors Buy Ono Pharmaceutical Co. (OPHLF) Stock?
Your note
Sign in to keep a note on OPHLF — it syncs with the Stock Master app.